**Operator:**
Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2025 Financial Results Conference Call.

*Operator instructions. Please be advised that this call is being recorded at the company’s request.*

At this time, I’d like to turn it over to David Krempa, Chief Business Officer at Eton Pharmaceuticals. Please proceed.

—

**David Krempa, Chief Business Officer:**
Thank you, operator. Good afternoon, everyone, and welcome to Eton’s Third Quarter 2025 Conference Call.

This afternoon, we issued a press release that outlines the topics we plan to discuss on today’s call. The release is available on our website at [etonpharma.com](https://etonpharma.com).

Joining me on our call today are Sean Brynjelsen, our CEO; James Gruber, our CFO; and Ipek Trinkaus, our Chief Commercial Officer.

In addition to taking live questions during today’s call, we will be answering questions that are emailed to us. Investors can send their questions to [[email protected]](mailto:[email protected]).

Before we begin, I would like to remind everyone that remarks made during the call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company’s filings with the SEC.

Now I will turn the call over to our CEO, Sean Brynjelsen.
https://seekingalpha.com/article/4839967-eton-pharmaceuticals-inc-eton-q3-2025-earnings-call-transcript?source=feed_all_articles